Monday was a very good news day for HDII
While the earnings announcement (http://biz.yahoo.com/prnews/010514/mnm017.html) was unremarkable, the news within the earnings story (and in a subsequent news release) was excellent. Here's the important paragraph from the earnings release:
>>``Results for the third quarter continue to be in line with our expectations,'' said Greg H. Guettler, President. ``The introduction of the CVProfilor(TM) DO-2020 CardioVascular Profiling System began at the end of the third quarter and, as such, was not as yet in a position to contribute to that quarter's sales. In support of the CVProfilor(TM) market introduction, sales, marketing and general and administrative expenses have increased during the third quarter. Furthermore, since our marketing strategy continues to include marketing of the CVProfilor(TM) on a 'per-patient-tested' basis, revenue will be progressive as the product placements grow. <<
The scaling up of the company is detailed in yesterday's 2nd news release :
---------------------
Hypertension Diagnostics Adds Key Personnel to Support Future Growth; New Sales, Customer Service and Engineering Positions Added
ST. PAUL, Minn., May 14 /PRNewswire/ --
Hypertension Diagnostics, Inc. (Nasdaq: HDII; HDIIW; HDIIU; HDIIZ), announced today a number of newly filled positions to support the commercial distribution of its CVProfilor (TM) DO-2020 CardioVascular Profiling System throughout the United States.
Greg H. Guettler, President of HDI, said, ``Just 60 days ago, we announced the beginning of our Phase I controlled product rollout of the CVProfilor(TM) DO-2020 CardioVascular Profiling System. Since then, we have introduced our technology at the Annual Meeting of the American College of Physicians - American Society of Internal Medicine (ACP-ASIM) held in Atlanta, Ga. and at the American College of Cardiology in Orlando, Fla. At the same time, we successfully recruited a number of talented and experienced individuals to fill key management positions that will directly support the future sales growth of our CVProfilor(TM) System.
``We are beginning to see acceptance of our pricing, marketing and reimbursement expectations for the CVProfilor(TM). As a result, we have added to the professional organization we had in place to fully capitalize on the opportunities we see in the large market of physicians, clinics and healthcare facilities throughout the United States,'' Guettler said.
New management appointments announced today by HDI include:
E. Paul Maloney, Vice President-Engineering;
Frank Tappen, Director of U.S. Sales;
Jeff Tonkinson, Director of Software Engineering;
Roxanne ``Rocky'' DeMarre, Customer Service Manager;
Dan Costelloe, Northwest Regional Sales Manager;
Paul Quinn, Southwest Regional Sales Manager.
``Each new member of our team brings to HDI extensive experience in their area of responsibility and a proven track record of accomplishment that will enable us to capitalize on our aggressive expectations for growth,'' Guettler said. ``With Regional Sales Managers already in place for the Midwest and Southeast Regions, we are now almost fully staffed to take the distribution of our proven technology to the next level. We intend to announce the addition of one to two regional sales managers for the northeast soon.
``We are pleased with the reception that our CVProfilor(TM) technology received at the two medical conferences in which we recently participated. For example, at the ACP-ASIM meeting in Atlanta, we conducted more than 200 demonstration tests reflecting a high level of interest on the part of the physicians who reviewed our technology. Over the next six weeks, we will demonstrate the CVProfilor(TM) at the Sixteenth Scientific Meeting and Exposition of the American Society of Hypertension in San Francisco and the 61st Scientific Sessions of the American Diabetes Association in Philadelphia. Both of these prestigious conferences represent an ideal setting to further extend the visibility of our proven technology which has been cleared for marketing by the FDA,'' Guettler said.
(abridged)
biz.yahoo.com
---------------------
The stock is up 30+% in the last two trading days. |
